GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ChromaDex Corp (NAS:CDXC) » Definitions » PS Ratio

ChromaDex (ChromaDex) PS Ratio : 3.39 (As of May. 06, 2024)


View and export this data going back to 2008. Start your Free Trial

What is ChromaDex PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, ChromaDex's share price is $3.78. ChromaDex's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.12. Hence, ChromaDex's PS Ratio for today is 3.39.

Warning Sign:

ChromaDex Corp stock PS Ratio (=3.39) is close to 2-year high of 3.61

The historical rank and industry rank for ChromaDex's PS Ratio or its related term are showing as below:

CDXC' s PS Ratio Range Over the Past 10 Years
Min: 1.15   Med: 6.27   Max: 20.23
Current: 3.39

During the past 13 years, ChromaDex's highest PS Ratio was 20.23. The lowest was 1.15. And the median was 6.27.

CDXC's PS Ratio is ranked better than
75.4% of 996 companies
in the Biotechnology industry
Industry Median: 9.145 vs CDXC: 3.39

ChromaDex's Revenue per Sharefor the three months ended in Dec. 2023 was $0.28. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.12.

During the past 12 months, the average Revenue per Share Growth Rate of ChromaDex was 7.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was 4.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was 12.40% per year. During the past 10 years, the average Revenue per Share Growth Rate was 13.20% per year.

During the past 13 years, ChromaDex's highest 3-Year average Revenue per Share Growth Rate was 26.90% per year. The lowest was -15.50% per year. And the median was 6.70% per year.

Back to Basics: PS Ratio


ChromaDex PS Ratio Historical Data

The historical data trend for ChromaDex's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ChromaDex PS Ratio Chart

ChromaDex Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.31 4.95 3.73 1.63 1.28

ChromaDex Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.63 1.42 1.42 1.31 1.28

Competitive Comparison of ChromaDex's PS Ratio

For the Biotechnology subindustry, ChromaDex's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ChromaDex's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ChromaDex's PS Ratio distribution charts can be found below:

* The bar in red indicates where ChromaDex's PS Ratio falls into.



ChromaDex PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

ChromaDex's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=3.78/1.115
=3.39

ChromaDex's Share Price of today is $3.78.
ChromaDex's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.12.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


ChromaDex  (NAS:CDXC) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


ChromaDex PS Ratio Related Terms

Thank you for viewing the detailed overview of ChromaDex's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ChromaDex (ChromaDex) Business Description

Traded in Other Exchanges
Address
10900 Wilshire Boulevard, Suite 600, Los Angeles, CA, USA, 90024
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segment namely Consumer Products, Ingredients segment and Analytical Reference Standards and Services. Majority of the revenue is earned from Consumer Products segment.
Executives
Brianna Gerber officer: SVP Finance / Interim CFO C/O CHROMADEX, INC., 1735 FLIGHT WAY, SUITE 200, TUSTIN CA 92782
Champion River Ventures Ltd 10 percent owner C/O 7F, CHEUNG KONG CENTER, 2 QUEEN'S ROAD, CENTRAL K3 00000
Jaksch Frank L Jr director, 10 percent owner, officer: Chief Executive Officer 10005 MUIRLANDS BOULEVARD, SUITE G FIRST FLOOR, IRVINE CA 92618
Robert N Fried director 100 NORTH CRESCENT DRIVE, BEVERLY HILLS CA 90210
Steven D Rubin director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Li Ka Shing 10 percent owner 79 DEEP WATER BAY ROAD, HONG KONG F4 00000
Chau Hoi Shuen Solina Holly 10 percent owner SUITES PT. 2909 & 2910, HARBOUR CENTRE, 25 HARBOUR ROAD, WANCHAI K3 999077
Hamed Shahbazi director C/O CHROMADEX, INC., 1735 FLIGHT WAY, SUITE 200, TUSTIN CA 92782
Ann Cohen director C/O CHROMADEX CORPORATION, 10900 WILSHIRE BLVD. STE 600, LOS ANGELES CA 90024
Kristin Patrick director 3329 CAY DRIVE, SHERMAN OAKS CA 91423
Ng Wang Yu Gary director ROOM 1709 HARBOUR CENTER, 25 HARBOUR ROAD, WANCHAI K3 -
Caroline S Levy director 2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431
Stephen A Block director INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 WEST 57TH ST, NEW YORK NY 10019
Lisa Hatton Harrington officer: General Counsel 53 SEA TERRACE, NEWPORT COAST CA 92657
Kevin M Farr officer: Chief Financial Officer MATTEL, INC., 333 CONTINENTAL BLVD, M1-1518, EL SEGUNDO CA 90245

ChromaDex (ChromaDex) Headlines

From GuruFocus

ChromaDex to Participate in the LD Micro Invitational XIII

By Business Wire Business Wire 05-30-2023